| Name | INH14 | 
|---|
| Description | INH14 is a cell permeable inhibitor of IKKα/IKKβ, with IC50s of 8.97 and 3.59 μM, respectively. INH14 inhibits the IKKα/β-dependent TLR inflammatory response. INH14 also inhibits downstream of TAK1/TAB1 and NF-kB pathways. Anti-inflammatory and anti-cancer activity[1]. | 
|---|---|
| Related Catalog | |
| Target | IKKβ:3.59 μM (IC50) IKKα:8.97 μM (IC50) | 
| In Vivo | INH14 (5 µg/g, i.p. for 2 hours) reduces lipopeptide-induced inflammation in mice[1]. Animal Model: 8-week old, male, pathogen-free C57BL/6J mice[1] Dosage: 5 µg/g, one hour before Pam2CSK4 injection Administration: I.P. for 2 hours Result: Decreased TNFα production in mice. | 
| References | 
| Molecular Formula | C15H16N2O | 
|---|---|
| Molecular Weight | 240.30 | 
| Storage condition | 2-8℃ |